Consensus Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Real-time Estimate Cboe BZX Other stock markets 01:29:59 2024-05-20 pm EDT			5-day change	1st Jan Change
20.51 ^USD	-0.29%		+6.64%	-9.81%

May. 13	Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Aerovate Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8b7f18.xRU4JoIroc-8GpajR-aqAEizKZN9f8nczeRtfixcScM.in1tdNRj0Yfma-HMPtLmaAPXQ6A5Hr-VqqAVGkIaIaWqJQBxyRL2_cRirg~9a13714caced3035fe28d770fef813fe

Analyst Recommendations on Aerovate Therapeutics, Inc.

Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	Apr. 12	MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	Apr. 04	MT
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	Mar. 21	MT
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	23-08-15	MT
Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating	23-05-17	MT
Guggenheim Initiates Aerovate Therapeutics at Buy With $36 Price Target	23-03-01	MT
Wedbush Raises Aerovate Therapeutics' PT to $54 From $27 on Increased Confidence in Inhaled TKIs, AV-10; Keeps Outperform Rating	22-12-12	MT
BTIG Upgrades Aerovate Therapeutics to Buy From Neutral, Price Target Is $27	22-12-06	MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at Outperform With $27 Price Target, Down From $32	22-09-19	MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at $27, Down From $32; Outperform Rating Kept	22-09-19	MT
Wedbush Lifts Price Target on Aerovate Therapeutics to $32 From $23, Keeps Outperform Rating	22-08-17	MT
BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	22-08-16	MT
BTIG Initiates Aerovate Therapeutics at Buy With $24 Price Target	22-02-11	MT
AEROVATE THERAPEUTICS : Evercore ISI Group Initiates Aerovate Therapeutics at Outperform Rating With $30 Price Target	21-07-26	MT
AEROVATE THERAPEUTICS : Jefferies Starts Aerovate Therapeutics at Buy With $21 Price Target	21-07-26	MT
AEROVATE THERAPEUTICS : Cowen Initiates Coverage on Aerovate Therapeutics With Outperform Rating	21-07-26	MT
AEROVATE THERAPEUTICS : Wedbush Starts Aerovate Therapeutics at Outperform With $23 Price Target	21-07-26	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.57 USD

Average target price

44.67 USD

Spread / Average Target

+117.14%

High Price Target

65 USD

Spread / Highest target

+215.99%

Low Price Target

27 USD

Spread / Lowest Target

+31.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Aerovate Therapeutics, Inc.

Wedbush
Guggenheim
BTIG
Jefferies & Co.
Cowen
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar